The Agenda

 

 

New vaccine & immuno-oncology profiling technology is
changing the whole industry

 

World Vaccine Congress Europe is a multi-faceted conference experience with over 200 industry leading speakers, 3 conferences, 80+ exhibitors & 700+ attendees providing the most exciting vaccine event on the planet. It is carefully curated by an experienced team who are plugged into a global network.

Our presenters are disruptors and visionary industry leaders from the biopharma industry. They are selected for their relevance, dynamism and insight. 

 

Barcelona, 28 - 31 October 2019

Schedule

Create your personal agenda –check the favourite icon

Oct 2810:00
Conference pass

Workshop A: Funding & Investment for Animal Health

Keynotes
What investment opportunities are there to support innovation in the animal health biologics field? Attend this workshop to hear about how to secure funding and create strategic partnerships from private and public funding bodies as well as the big pharma leading the industry.
Oct 2810:00
Conference pass

Workshop B: Vaccine Market Access and Regulatory Affairs for Global Health

Keynotes
The market for vaccines is more complex than most and there are many definitions of what constitutes a healthy market – one that ensures sustainable, sufficient, relevant, predictable supply to meet demand. There are a complex, interconnected set of factors that together comprise the market place, including the regulatory environment, the incentives or disincentives for investing in new innovation and R&D, how the value of vaccines are assessed, the procurement of vaccines, as well as the infrastructure for delivery of and access to vaccines. How global, regional, and national stakeholders, including government authorities, multi-laterals, NGOs, and industry, make decisions and act in the marketplace can determine the health or the fragility of the vaccine market in the short and long-term. This session will explore what we mean by a healthy vaccine market, the various factors that comprise the market, and factors that can enable or impede a healthy market.
  • Overview of global vaccine market and describing the characteristics of a healthy market (review of current frameworks)
  • Insights from the introduction of new vaccines and strategies that have been leveraged to encourage sustainable, sufficient, relevant, predictable supply to meet demand – what’s worked and what hasn’t in different contexts, including LMICs
  • Opportunities for greater collaboration across stakeholders, including industry, to think holistically about vaccine markets and address key challenges that undermine the health of the market
Moderator: Dr Julia Spencer, Associate Vice President, Global Vaccine Public Policy, Partnerships, MSDUnited States
Ariane Mccabe, Director, Global Health And Public Affairs, GlaxoSmithKlineSwitzerland
Oct 2814:00
Conference pass

Workshop C: Active & passive immunity: How do we induce maternal immunisation in human and animals?

Keynotes
Maternal immunity plays a pivotal role in human & animal health, but what do we understand? Is the veterinary vaccine industry more advanced than human? What can we learn from each other to move the field forward?
Oct 2814:00
Conference pass

Workshop D: Improvement of cancer patient treatment outcomes: Using liquid biopsies & novel biomarkers for predicting prognosis and response

Keynotes
Biomarker Strategy
Moderator: Prof Karen-Lise Spindler, Aarhus UniversityDenmark
Tony Whetton, Director, Stoller Biomarker Discovery CentreUnited Kingdom
Dr Yong-Jie Lu, Professor In Molecular Oncology, Queen Mary University of LondonUnited Kingdom

Create your personal agenda –check the favourite icon

Oct 2908:30
Conference pass
Oct 2908:40
Conference pass

Paradigm shift in vaccine funding capacity and collaborations for disease X and persistent epidemics

Keynotes
  • How are we incentivizing vaccine development?
  • How will these vaccines reach the LMICs and developing countries?
  • CEPI’s strategy and investment to advance medical countermeasures to emerging diseases
  • The potential of translational medicine and access for all
  • How to secure public funding to advance research and vaccine development
Oct 2909:25
Conference pass

Are we pandemic ready for influenza? How to close the gaps in our current strategy in preparedness

Keynotes
  • How to close the gaps in our current strategy in preparedness
  • What is our response mechanism in medical and non-medical interventions?
  • European wide actions to provide global health, sustainable policies, coverage and access – joint procurement
  • The role of industry in vaccine matching, manufacturing and antivirals
Oct 2910:10
Conference pass

What will 2020 hold for immuno-oncology? A global landscape and overview of promising approaches

Keynotes
  • Emerging immuno-oncology targets and modalities
  • Exploring possible uses of artificial intelligence in oncology (patient stratification, predicting patient response to treatment, AI as a diagnostic tool etc)
  • Ensuring patient centricity in oncology clinical trials
  • Looking to the future: How can we go further to make precision medicine a reality for cancer patients?
Oct 2911:40
Conference pass

Are PD-1 Antibodies transforming cancer therapy?

Keynotes
Oct 2911:40
Conference pass

Biodefence: The role of vaccines in preventing outbreaks, through natural causes or biothreats

Keynotes
Oct 2911:40
Conference pass

CEPI: CFP2 rolling call

Keynotes
Oct 2911:40
Conference pass

Challenges in trial design, implementation and safety assessment under clinical development

Keynotes
  • Challenges in Phase IV studies and register based impact research
  • Post-licensure safety studies using real world data
Oct 2911:40
Conference pass

Challenges of universal influenza vaccines evaluation

Keynotes
Oct 2911:40
Conference pass

Development pathways for combining immune-based therapies in cancer: leveraging disease biology, complex biomarkers, regulatory approval and pathways to adoption

Keynotes
Oct 2911:40
Conference pass

Do we understand the biology behind cold and hot tumours, which is needed for successful treatment and what is the role for biomarkers?

Keynotes
Oct 2911:40
Conference pass

Establishing a One Health approach to combat emerging zoonotic & transboundary diseases

Keynotes
Oct 2911:40
Conference pass

Further follow up on: Are we pandemic ready for influenza? How to close the gaps in our current strategy in preparedness

Keynotes
Oct 2911:40
Conference pass

Further follow up on: Paradigm shift in vaccine funding capacity and collaborations for disease X and persistent epidemics

Keynotes
Oct 2911:40
Conference pass

Human Challenge studies: Dengue, Zika, Ebola: How far can we go?

Keynotes
Oct 2911:40
Conference pass

Intradermal delivery of therapeutic vaccines – benefits and challenges

Keynotes
Oct 2911:40
Conference pass

Practical use of systems biology in vaccinology

Keynotes
Oct 2911:40
Conference pass

Strategies for selecting the right immuno-oncology tumour model

Keynotes
Oct 2911:40
Conference pass

Strengthening human & animal public health systems at their interface to prevent AMR: Spanish National Action Plan against Antimicrobial Resistance

Keynotes
Oct 2911:40
Conference pass

Unique Operational Challenges for Vaccines Clinical Development.

Keynotes
Oct 2911:40
Conference pass

Virtual trials—do they have a role in vaccine studies

Keynotes
Oct 2914:40
Conference pass
Oct 2914:40
Conference pass

Chair’s opening remarks

Immuno-oncology
Oct 2914:40
Conference pass
Oct 2914:40
Conference pass

Chair’s opening remarks

Emerging Diseases
Jakob Cramer, Head Of Clinical Development, CEPI
Oct 2914:40
Conference pass

Chair's opening remarks

Companion Animals
Patrick Frayssinet, R&D Director, URODELIAFrance
Oct 2914:45
Conference pass
Oct 2914:45
Conference pass

Developing novel combination immunotherapies for cervical cancer and head-and-neck cancer

Immuno-oncology
- Clinical Updates on Phase II trial ISA101b and cemiplimab
Oct 2914:45
Conference pass
Oct 2914:45
Conference pass

The first EMA approved veterinary stem cell therapy: Ubi Sumus, Quo Vadimus?

Companion Animals
(Where are we and where are we going to)
Oct 2914:45
Conference pass
Oct 2914:45
Conference pass
Oct 2915:15
Conference pass

Dengue vaccine trials in development

Emerging Diseases
Ricardo Palacios, Instituto ButantanBrazil
Oct 2915:15
Conference pass

Exploring the crossover between human and veterinary applications for stem cells

Companion Animals
Oct 2915:15
Conference pass

Harmonising priorities in Europe: Role of public health, government strategies and industry to halting the AMR crisis – do we have a consistent message?

AMR
Insight and progress from international healthcare agencies; How can regulatory and access policies can be used to strengthen utilization of vaccines in our international action plans to address AMR?
Magda Chlebus, Executive Director, Science Policy And Regulatory Affairs, EFPIABelgium
Bryan Deane, New Medicines, ABPIUnited Kingdom
Oct 2915:15
Conference pass

Hope for late-stage ovarian cancer: Development of a personalized dendritic cell vaccine

Immuno-oncology
Oct 2915:15
Conference pass

Update in the clinical development of a plant-derived quadrivalent Virus-Like Particles influenza vaccine

Influenza & Respiratory
Oct 2915:15
Conference pass

Working towards control and eradication of African swine fever (ASF) in the EU

Veterinary
Oct 2915:45
Conference pass
Oct 2915:45
Conference pass

Autologous cancer stem cell vaccines for solid tumor cancers

Immuno-oncology
Oct 2915:45
Conference pass

Collaborative efforts with WRAIR on the development of an inactivated Zika vaccine

Emerging Diseases
Oct 2915:45
Conference pass

Developing species-specific therapeutic monoclonal antibodies that address the demand for innovative therapies for companion animals

Companion Animals
Oct 2915:45
Conference pass

New on the block: Ph1 trial results on a Chikungunya vaccine candidate

New Technology
A new vaccine based on recombinant viral vectors
Oct 2915:45
Conference pass
Oct 2916:00
Conference pass

Chikungunya in clinical development – an update & Update on our first CEPI program with Lassa and MERS

New Technology
Oct 2916:15
Conference pass

Call to action: How the innovative vaccines industry is contributing to fight against AMR

AMR
Dr Julia Spencer, Associate Vice President, Global Vaccine Public Policy, Partnerships, MSDUnited States
Oct 2916:15
Conference pass

Clinical Updates: Development of effective vaccines approaches against African swine fever virus

Veterinary
Oct 2916:15
Conference pass

Next generation companion animal therapeutic biologics and manufacturing

Companion Animals
Oct 2916:15
Conference pass

Next generation mRNA cancer vaccine approaches and intratumoral immunomodulation

Immuno-oncology
Oct 2916:15
Conference pass

VaXIMISER – new eggs and cells for maximising vaccine production

Influenza & Respiratory
Andrew Bean, Chief Technology Officer, Commonwealth Scientific and Industrial Research OrganisationAustralia
Oct 2916:30
Conference pass

Alternative needle-free delivery devices advancing vaccine development

New Technology
Oct 2916:30
Conference pass

New flu data towards a universal flu vaccine

Influenza & Respiratory
Oct 2916:30
Conference pass

Overview of the Ebola vaccine results from the 2013 – 2016 outbreak, the requirement for improvements in the field

Emerging Diseases
Oct 2917:15
Conference pass

A DNA vaccine against MERS vaccine Generates High Levels of Antibodies and Induces Broad-based T Cell Responses in Phase 1 Study

New Technology
Oct 2917:15
Conference pass

AMR: Overcoming hurdles to increase the vaccination of animals

Veterinary
Oct 2917:15
Conference pass

Building international capacity to tackle AMR more efficiently – is this in line with Europe?

AMR
Stewardship & social behaviour change in Europe – do we have measurable push & pull outcomes?
Oct 2917:15
Conference pass

Building international capacity to tackle AMR more efficiently – is this in line with Europe?

Companion Animals
Stewardship & social behaviour change in Europe – do we have measurable push & pull outcomes?
Oct 2917:15
Conference pass

Developing personalized neoantigen cancer vaccines to target solid tumors

Immuno-oncology
- Inducing a unique CD8-dominated T cell response- Clinical updates on phase I/IIa VB10.NEO vaccine trial
Oct 2917:15
Conference pass

New immune-data and correlates analysis on our Ebola vaccine

Emerging Diseases
Jerry Sadoff, Senior Advisor, JanssenNetherlands
Oct 2917:15
Conference pass

The Human Vaccines Project: Efforts towards a Universal flu vaccine

Influenza & Respiratory
What has all this data told us?
Oct 2917:30
Conference pass

Overcoming current limitations in selecting immunogenic neoantigens- The NeoScreen platform

Immuno-oncology
Oct 2917:30
Conference pass

The use of vaccination to treat chronic allergic diseases in companion animals

Companion Animals
Martin Bachmann, Professor of Immunology, University of BernSwitzerland
Oct 2917:45
Conference pass

Characterizing immune signatures to malaria for better correlates of protection

Emerging Diseases
What the long-term effect and longevity of RTSS vaccine?
Oct 2917:45
Conference pass

eVLPs as an antigen delivery & immunomodulatory platform in cancer

Immuno-oncology
Oct 2917:45
Conference pass

Photochemical internalisation (fimaVacc) – a novel technology for enhancing cellular immune responses with protein and peptide based vaccines

New Technology
Oct 2917:45
Conference pass

Rift Valley fever vaccines: current and future needs

Veterinary
Oct 2917:45
Conference pass

Universal flu vaccine candidate

Influenza & Respiratory
Oct 2918:00
Conference pass

Autologous therapeutic cancer vaccine from companion animal to human

Companion Animals
Patrick Frayssinet, R&D Director, URODELIAFrance
Oct 2918:00
Conference pass

Development of new adjuvants for oral vaccines, study of their mechanism of action and uses thereof

New Technology
Oct 2918:00
Conference pass

First phase I results from a novel universal flu vaccine candidate?

Influenza & Respiratory
Oct 2918:00
Conference pass

NousCom neoantigen-based cancer vaccine for potent and effective anti-tumor T cell immunity

Immuno-oncology

Create your personal agenda –check the favourite icon

Oct 3009:00
Conference pass
Oct 3009:00
Conference pass

Chair’s opening remarks

Emerging Diseases
Jerry Sadoff, Senior Advisor, JanssenNetherlands
Oct 3009:00
Conference pass

Chair’s opening remarks

Bioprocess & Manufacture


Oct 3009:05
Conference pass

From a mathematical model to a novel universal influenza vaccine

Bioprocess & Manufacture
Sunetra Gupta, Professor, University of OxfordUnited Kingdom
Oct 3009:05
Conference pass

Immunotherapy in 2020: Beyond checkpoint inhibition and CAR T cells

Immuno-oncology
Oct 3009:05
Conference pass

New reverse genetics systems to complement the RSV toolbox: Preclinical and clinical tools

Influenza & Respiratory
Martin Ludlow, Group Leader, Research Center for Emerging Infections and Zoonoses (RIZ)Germany
Oct 3009:15
Conference pass

The transfer of AMR bacteria between humans and animals and where we can interfere the best (and what the result can be)

AMR
Oct 3009:35
Conference pass

Formulation considerations for the development of adjuvanted vaccines

Bioprocess & Manufacture


Oct 3009:35
Conference pass

How do we overcome adoptive cell therapy limitations to enable the treatment of more patients?

Immuno-oncology
- Novel approach to target solid tumours
Oct 3009:35
Conference pass

Prospects for the antibiotics pipeline and antibiotic alternatives

AMR
Drug development to meet the challenge of antimicrobial resistance
Oct 3009:35
Conference pass

RSV adaptive immunity assays: what do we need?

Influenza & Respiratory
Oct 3010:05
Conference pass

Development of novel S2 insect cell lines enabling production of improved vaccines

Bioprocess & Manufacture


Oct 3010:05
Conference pass

Engineering of African Swine Fever virus for production of live attenuated vaccine candidates

Veterinary
Oct 3010:05
Conference pass

MERS and Lassa vaccines development

Emerging Diseases
Oct 3010:05
Conference pass

Rational development of functionalized nanobiomaterials as novel immunotherapies for cancer treatment

Immuno-oncology
Oct 3010:05
Conference pass

The ferret as an animal model to study Respiratory Syncytial Virus infection, transmission and countermeasures

Influenza & Respiratory
Oct 3010:05
Conference pass

The impact of PCV13 in Capita on non bacteremic pneumonia and how to improve on efficacy

AMR
Will conjugates on alum suffice?
Oct 3010:20
Conference pass

Affinity chromatography for vaccines purification: EU DiViNe project provides proof of concept

Bioprocess & Manufacture


Oct 3011:35
Conference pass

Fill & finish of live vaccines – A CDMO perspective

Bioprocess & Manufacture


Oct 3011:35
Conference pass

Insight on future combination strategies

Immuno-oncology
- Are we effectively incorporating profiling techniques into R&D to better understand the underlying cellular mechanisms and “build” better combinations?
Oct 3011:35
Conference pass

Next-generation adjuvants: Transferring the learnings of its use in humans to veterinary health, an African perspective

Veterinary
Oct 3011:35
Conference pass

Progress on CMV vaccines and antibody therapies

Emerging Diseases
  • Development of a CMV vaccine based on non-replicating lymphocytic choriomeningitis virus vectors
  • PhII data on a MVA based vaccine for the transplant space
  • Title TBC
Oct 3012:05
Conference pass

Flexible and Scalable Strategies for Upstream Vaccine Processing from Development to Manufacturing Supported by Integrated Process Analytical Technologies

Bioprocess & Manufacture
Oct 3012:05
Conference pass

Large animal challenge models for assessment of human and veterinary negative strand virus recombinant vaccines

Veterinary
Oct 3012:05
Conference pass

Targeting myeloid derived suppressor cells (mdsc) to improve efficacy of checkpoint inhibitors

Immuno-oncology
Oct 3012:05
Conference pass

Update on Janssen RSV vaccine and use of human RSV challenge model

Influenza & Respiratory
Dr Benoit Callendret, Cdtl, Janssen VaccinesNetherlands
Oct 3012:15
Conference pass

Large animal challenge models for assessment of human and veterinary negative strand virus recombinant vaccines

Veterinary
Oct 3012:35
Conference pass

Cancer genomics and immunotherapy: predicting response and illuminating disease biology

Immuno-oncology
Oct 3012:35
Conference pass

High cell concentration banking for seed train reduction on fluoropolymer single use bag

Bioprocess & Manufacture


Oct 3012:35
Conference pass

How implementation of the DNA Fish vaccine in Europe can change the vaccination landscape for other veterinary species

Veterinary
Tyre Grant, Senior Director, ElancoUnited States
Oct 3012:35
Conference pass

Ph 3 RSV F nanoparticle maternal RSV vaccine

Influenza & Respiratory
Oct 3013:05
Conference pass

Biomarker strategies for patient selection

Immuno-oncology
- Rationale for creating a reference standard for biomarker assays- Clinical implementation of biomarker assays - How do we get these assays up and running in clinical practice?

Oct 3013:05
Conference pass

From bench to clinical trial: feeding the value chain

Influenza & Respiratory
Oct 3013:05
Conference pass

Scalable in vitro manufacturing of tailored vaccines

Bioprocess & Manufacture
Oct 3013:05
Conference pass

The current status of autologous & autogenous vaccines development in Europe

Veterinary
Oct 3013:05
Conference pass

Why is a Staph aureus vaccine so challenging?

AMR
Oct 3013:20
Conference pass

Development of a new manufacturing platform technology for human vaccines

Bioprocess & Manufacture


Oct 3015:05
Conference pass

Development of a novel agent (MSC-1) to reactivate an immune response by LIF blockade

Immuno-oncology
Oct 3015:05
Conference pass

Overview of QbD application to vaccines development, with practical examples

Bioprocess & Manufacture


Oct 3015:05
Conference pass

Regulatory and operational aspects of GMO vaccines studies

Clinical Development
Oct 3015:05
Conference pass

Vaccine against AECOPD: clinical progress and strategic challenges

AMR
Oct 3015:05
Conference pass

Vaccinomics approach to control vector-borne diseases

Veterinary
Professor Jose De La Fuente, Head Of Genomics Group, Instituto De Investigacion En Recursos Cinegeticos Ronda De Toledo S/NSpain
Oct 3015:35
Conference pass

Development of anti-tick vaccines to control tick-borne viruses

Veterinary
Oct 3015:35
Conference pass

Monitor vaccination studies using Repertoire Sequencing and the IGX Platform

Immuno-oncology
Oct 3015:35
Conference pass

Process development of a novel low-cost liquid rotavirus vaccine to meet global demand

Bioprocess & Manufacture


Oct 3015:35
Conference pass
Oct 3015:35
Conference pass

When preparation meets opportunity: reducing the odds of failure in Late Phase

Clinical Development
Oct 3015:50
Conference pass

MVA-VLP as a safe and effective platform for delivery of multi-antigens for infectious diseases and cancer

Immuno-oncology
Oct 3016:35
Conference pass

Case study: Applying artificial intelligence in cancer treatment response prediction

Immuno-oncology
Oct 3016:35
Conference pass

E.coli UTI and bacteremia epidemiology

AMR


Oct 3016:35
Conference pass

Exploration and design of novel vaccination strategies for controlling parasites

Veterinary
Oct 3016:35
Conference pass

HIV vaccine trials: NIH perspective and challenges

Emerging Diseases
Oct 3016:35
Conference pass

How can we achieve sustainable vaccine manufacturing?

Bioprocess & Manufacture


Oct 3016:35
Conference pass

How site’s can be a useful part of protocol development process

Clinical Development
Oct 3016:50
Conference pass

Panel: The role of biomarkers in vaccine development and licensure

Clinical Development
  • Pertussis, MenB, Influenza and emerging diseases
  • Regulatory requirements
Oct 3017:05
Conference pass
Oct 3017:35
Conference pass

Comparing traditional vaccine manufacturing to mRNA vaccine manufacturing

Bioprocess & Manufacture


Oct 3017:35
Conference pass

Modelling cancer pharmacogenomics

Immuno-oncology
Oct 3017:35
Conference pass

Mucosal vaccines in veterinary species: Lessons from E. coli vaccinations in pigs

Veterinary
Oct 3017:35
Conference pass

Typhoid Conjugate Vaccine

AMR


Dr Sushant Sahastrabuddhe, Director, Enteric Fever, International Vaccine InstituteRepublic Of Korea

Create your personal agenda –check the favourite icon

Oct 3109:00
Conference pass
Oct 3109:00
Conference pass
Oct 3109:00
Conference pass
Oct 3109:00
Conference pass
Oct 3109:00
Conference pass

Chair’s opening remarks

Bioprocess & Manufacture
Oct 3109:10
Conference pass

Accelerating vaccine process development and increasing productivity with single use intensified processing and predictive process control - Downstream Processing

Bioprocess & Manufacture
Oct 3109:10
Conference pass

Economics, vaccine development and the burden of animal disease

Veterinary
William Gilbert, Lead Economic Analyst, H2020 SAPHIR Project, University of LiverpoolUnited Kingdom
Oct 3109:10
Conference pass

Panel: Building vaccine confidence and resilient immunization systems – The role of communications

Vaccine Safety
  • The role of communications in vaccine hesitancy and confidence?
  • How can stakeholders from patient advocates, journalists, healthcare providers, policymakers to industry
  • Apply behavioural science insights to shape more effective communications around vaccination and improve vaccination acceptance?
  • What are the attributes of a resilient immunization system, and how can we collaborate to manage threats to vaccine confidence and better anticipate and mitigate issues in the future?
Oct 3109:10
Conference pass

Unlocking the potential of oncolytic viruses to target cancer cells

Immuno-oncology
Clinical Updates on Vyriad’s Voyager-V1 Program
Oct 3109:10
Conference pass

World Bank collaboration and its capacity for vaccine trials in emerging countries (strategy and plans)

Partnerships
Oct 3109:40
Conference pass

Accelerating livestock vaccine development for LMICs; How can industry help?

Veterinary
Oct 3109:40
Conference pass

How introduction of single use and high through put equipment in fermentation change the process development way of working?

Bioprocess & Manufacture
Marjorie Monnet, Fermentation Unit Head, Sanofi PasteurUnited States
Oct 3109:40
Conference pass

Systemic delivery of localized combination immuno-gene therapy within the tumour microenvironment

Immuno-oncology
Oct 3109:40
Conference pass

The role of emerging markets in the global supply and demand for vaccines

Partnerships
Oct 3109:55
Conference pass

Bats, horses, pigs, people: One health countermeasures against hendra and nipah viruses

Veterinary
Oct 3110:10
Conference pass

EIB Venture Debt – Financing Innovation and Growth in Life Sciences

Partnerships
  • How the European Investment Bank and the EU Join Forces to Fight Infectious Diseases and Support Innovative European SMEs
Oct 3110:10
Conference pass

Exploiting a successful immunization platform to develop advanced immuno-oncology remedies

Immuno-oncology
Oct 3110:25
Conference pass

Comparative analysis of Nipah virus vaccine candidates in pigs

Veterinary
Oct 3111:20
Conference pass

Adult Vaccines – What’s needed for a rapidly changing demographic?

Vaccine Safety
  • Same data, different results: an archetype analysis of adult vaccine decision making and uptake in 34 countries
  • Adult Immunization Evidence & Policy: Issues for the next decade
  • Issues for implementation of adult immunization programs
  • Introducing the International Council on Adult Immunization
  • Panel with all speakers: Accelerating progress – what do we do differently?
Oct 3111:20
Conference pass

MERS prevention – developing a candidate vaccine for humans and camels

Veterinary
Oct 3111:20
Conference pass

Overcoming antibody drug development challenges

Immuno-oncology
-Translating antibody therapies to the clinic – The devil is in the detail
Oct 3111:20
Conference pass

Panel: Insights on how to implement new business partnership models for international collaboration among vaccine manufacturers and government

Partnerships
International collaborative research and partnering opportunities for vaccine development
Oct 3111:50
Conference pass

Driving successful antibody discovery and development

Immuno-oncology
Oct 3111:50
Conference pass

Panel: From development to commercialization of vaccines

Bioprocess & Manufacture
  • Lessons learned from various vaccine – hurdles to avoid in order to reach large scale manufacture
  • Are we incorporating computational modelling and AI for smarter manufacturing?
Oct 3111:50
Conference pass

Recent outbreaks of equine influenza and the potential new strain recommendations from OIE

Veterinary
Oct 3112:20
Conference pass

Next generation cancer immunotherapy using IL-2/antibody complexes

Immuno-oncology
Oct 3112:20
Conference pass

Vaccines in rural communities

Partnerships
Oct 3112:20
Conference pass
Oct 3114:00
Conference pass

What’s next? Working towards Immunology 2.0 and beyond

Keynotes
  • How has genomics, virology and epidemiology helped revolutionise the way we develop vaccines?
  • New scientific approaches to more targeted bacterial vaccines using computational modelling and mAb mapping
  • What progress has been made with all this new information to hand – is it translational?
  • What policy considerations and challenges should we anticipate with these technologies? Governmental challenges
Oct 3115:00
Conference pass

Eliminating (or Eradicating) Global Infectious Diseases

Keynotes
  • Is elimination of measles still viable?
  • What’s the vaccinations strategy to get there and how do we maintain this once a disease is eradicated?
  • What plans are in place for developing countries?
last published: 22/Oct/19 08:55 GMT